Aug 20, 2009
By:
Laura Bush
Protalix BioTherapeutics received approval from the US FDA on August 17 to proceed with its treatment protocol for prGCD, a development drug for Gaucher's disease.
|
Aug 12, 2009
By:
Laura Bush
The prospect of conducting risk assessments, as part of the quality risk management strategy promoted by the International Conference on Harmonization (ICH) Q9 guideline, tends to evoke blank stares and confusion. It also prompts many questions: Which of the many tools-PHA, HACCP, FMEA, etc.-should we use?
|
Aug 12, 2009
By:
Laura Bush
SAFC Biosciences (St. Louis, MO) has developed a chemically defined cell culture supplement based on the characterization of hydrolysate components proven to provide cell growth and protein production capabilities equivalent to traditional undefined hydrolysate raw materials.
|
Aug 6, 2009
By:
Laura Bush
Sartorius Stedim Biotech (Goettingen, Germany) and SAFC Biosciences (St. Louis, MO), a division of SAFC, have entered into a partnership to share expertise, support each other in developing custom solutions for customers, and generate data on the performance of equipment in different applications.
|
Perhaps the best way to regulate drugs is to regulate them not conservatively or liberally, but effectively.
Aug 1, 2009
By:
Laura Bush
Perhaps the best way to regulate drugs is to regulate them not conservatively or liberally, but effectively.
|
The truth is, we should have been afraid of H1N1, because the threat of a flu pandemic is real.
Jul 1, 2009
By:
Laura Bush
The truth is, we should have been afraid of H1N1, because the threat of a flu pandemic is real.
|
Jun 17, 2009
By:
Laura Bush
Genzyme Corporation has halted production at its manufacturing plant in Allston Landing, MA, because it has detected a virus that impairs cell growth in one of the six bioreactors there.
|
Importing foreign drugs is not the best way to increase access to medicine. The risks are too high, and it burdens the over-stretched FDA unfairly.
Jun 1, 2009
By:
Laura Bush
Importing foreign drugs is not the best way to increase access to medicine. The risks are too high, and it burdens the over-stretched FDA unfairly.
|
May 13, 2009
By:
Laura Bush
Members of the pharmaceutical and biotech industries have formed a new industry coalition, called "Rx-360," with the goal of improving supply chain safety.
|
|
